The short version: the tissue changes that follow menopause produce four symptoms that are routinely attributed to something else — recurrent urinary infections blamed on bad luck, urinary urgency labelled an overactive bladder, painful sex treated as a libido problem, and dryness managed with a lubricant when a regular moisturiser is what is needed. The condition is now usually called genitourinary syndrome of menopause, because it is not confined to the vagina. Unlike hot flashes it is progressive and does not resolve on its own, and the treatment with the strongest evidence is also the one most often avoided because of a warning label that does not apply to it.
Below are the four symptoms, what each gets mistaken for, and the treatment options in order of how well they are supported.
Why it is no longer called vaginal atrophy
The older term described only part of what happens. Estrogen receptors are present not just in the vaginal wall but in the urethra, the bladder trigone, the vulva and the pelvic floor. When estrogen falls after menopause, all of those tissues change: they become thinner, less elastic, less well vascularised and less able to maintain their protective environment.
That is why the symptoms extend into urinary function, and why treating it as a purely sexual or purely vaginal issue misses most of it. Genitourinary syndrome of menopause is the term now generally used.
The other difference from the rest of menopause matters more than the terminology.
Hot flashes and night sweats tend to diminish over several years whether or not they are treated. These tissue changes do not. They progress for as long as estrogen remains low, which means symptoms generally get worse with time rather than better. Nearly every woman who waits for this one to pass is waiting for something that will not happen.
The four symptoms, and what each is blamed on
| Symptom | Commonly attributed to | What is actually happening |
|---|---|---|
| Recurrent urinary tract infections | Hygiene, bad luck, sexual activity | Rising vaginal pH and loss of protective lactobacilli allow colonisation by urinary pathogens |
| Urgency, frequency, getting up at night | An overactive bladder, or ageing | Thinning of estrogen-responsive tissue in the urethra and bladder base |
| Pain with intercourse | Low libido, stress, a relationship issue | Thinner, less elastic, poorly lubricated tissue — the pain is physical and causes the loss of desire |
| Dryness, burning, irritation | Needing a lubricant | Reduced tissue hydration that needs regular moisturising, not friction reduction at the moment of use |
Two of these deserve expanding, because the misattribution does real harm.
Recurrent urinary infections. A healthy premenopausal vagina is acidic and dominated by lactobacilli, which suppresses the growth of the organisms that cause urinary infections. As estrogen falls the pH rises and that protective population declines. The result is repeated infections that get treated as isolated events with repeated antibiotic courses. There is reasonable evidence that treating the underlying tissue change with vaginal estrogen reduces recurrence. If you are on your third or fourth course of antibiotics, the question to raise is what is making you susceptible.
Painful sex read as a desire problem. The sequence is usually pain first, avoidance second, reduced desire third. Reversing that order in the explanation turns a treatable tissue problem into a vague psychological one, and women are often left feeling the problem is theirs to resolve emotionally. The pain has a physical cause and responds to physical treatment.
What to try, in order of evidence
| Option | What it does | How well supported |
|---|---|---|
| Vaginal moisturisers, used regularly | Hydrates tissue over time | Good for symptom relief; does not reverse tissue change |
| Lubricants at time of activity | Reduces friction during sex | Effective for that purpose only |
| Low-dose vaginal estrogen | Restores tissue thickness, elasticity and pH | Strongest evidence; widely considered first-line |
| Vaginal DHEA (prasterone) | Converted locally to sex steroids | Approved for painful sex from menopause; a non-estrogen option |
| Ospemifene (oral) | Acts selectively on vaginal tissue | Approved for moderate to severe painful sex |
| Pelvic floor physical therapy | Addresses coexisting muscle tension and pain | Useful where pelvic floor overactivity contributes |
| Energy-based and injectable treatments | Variable proposed mechanisms | Limited and contested; see below |
The first two are available without prescription and are a reasonable place to start for mild symptoms. The middle group requires a prescription and a conversation with a physician, which is appropriate — these are medical treatments for a medical condition.
About the warning label on vaginal estrogen
This causes more unnecessary suffering than any other single misunderstanding in this area, so it is worth stating plainly.
Systemic hormone therapy, taken as a pill or patch for hot flashes, delivers hormone throughout the body, and the large trials that generated the familiar warnings studied that kind of therapy. Low-dose vaginal estrogen is applied to the tissue itself at a small fraction of those doses, and systemic absorption is minimal.
The boxed warning that appears on vaginal preparations was applied as class labelling, extrapolated from the systemic studies rather than derived from studies of the vaginal products. Major menopause and women’s health organisations have stated that the warning is not supported by the available evidence for low-dose vaginal estrogen, and have called for it to be revised.
That is not a reason to self-prescribe. It is a reason to have the conversation rather than ruling the option out after reading the packaging. If you have a history of hormone-sensitive cancer, the discussion is genuinely more nuanced and belongs with your oncologist as well as your physician.
Where energy-based and injectable treatments sit
We think patients are owed a straight answer here, including about treatments offered in this field generally.
In 2018 the FDA issued a safety communication warning that energy-based devices were being marketed for vaginal rejuvenation and related symptoms without having been cleared for those indications, and citing reports of adverse events including burns, scarring and persistent pain. Several sham-controlled trials published since have not demonstrated benefit over placebo for these symptoms.
That does not mean no patient benefits, and there may be a role in carefully selected cases. It does mean these treatments should not be described as established, should not be presented as an alternative to treatment with better evidence, and should not be the first thing recommended to someone who has not yet tried a moisturiser or discussed vaginal estrogen.
Our position on which indications in this area have good support and which do not is set out on the vaginal revitalization page, and we will recommend the simpler option, or refer you, when that is the right answer.
A reasonable test of any provider in this field: ask what they would suggest if you wanted the option with the strongest evidence. If vaginal estrogen is not mentioned, you are being sold a service rather than advised on a condition.
What needs assessment rather than self-treatment
- Any bleeding after menopause — this always needs prompt evaluation and is never assumed to be atrophy
- A lump, ulcer, persistent sore area, or a change in the appearance of the vulval skin
- Pain that is severe, or localised to one spot
- Discharge with odour, or itching that does not settle — infection and inflammatory skin conditions can mimic or coexist with these changes
- Symptoms before the age of 40
Vulval skin conditions such as lichen sclerosus produce overlapping symptoms, need a different treatment, and have implications that make diagnosis worth getting right.
Common questions
Does vaginal atrophy get better on its own like hot flashes do?
No, and this is the most important difference between the two. Hot flashes and night sweats typically diminish over several years without treatment. Genitourinary syndrome of menopause is progressive — the tissue changes continue as long as estrogen remains low, so symptoms tend to worsen gradually rather than resolve. Waiting it out is effective for hot flashes and counterproductive here.
Can vaginal atrophy cause recurrent urinary tract infections?
Yes, and it is one of the more under-recognised consequences. The tissue of the vagina and lower urinary tract is estrogen-responsive. When estrogen falls, the vaginal pH rises and the protective lactobacilli population declines, which allows colonisation by organisms that cause urinary infections. There is reasonable evidence that treating the underlying tissue change with vaginal estrogen reduces the frequency of recurrent urinary tract infections in postmenopausal women, which is why repeated courses of antibiotics without addressing the cause is an incomplete approach.
Why does sex hurt, and is it a libido problem?
In most cases the pain comes first and the drop in desire follows it. Thinning, less elastic and less lubricated tissue makes penetration genuinely painful, and desire reasonably declines in response to anticipated pain. Treating it as a desire or relationship problem rather than a tissue problem is a common and frustrating misdirection. The pain itself is physical and treatable.
What is the difference between a lubricant and a vaginal moisturiser?
They do different jobs and are not interchangeable. A lubricant is used at the time of sexual activity to reduce friction, and its effect lasts minutes to hours. A vaginal moisturiser is used regularly, several times a week, independent of sexual activity, and works by hydrating the tissue over time. Many women are given a lubricant when regular moisturiser is what they need. Neither reverses the underlying tissue change, but both improve comfort and are reasonable first steps.
Is vaginal estrogen safe, given the warnings on the box?
This question deserves a direct answer because the labelling causes a great deal of avoidable suffering. Low-dose vaginal estrogen is applied locally and results in minimal systemic absorption, which is quite different from systemic hormone therapy taken for hot flashes. The boxed warning on vaginal preparations was extrapolated from studies of systemic therapy rather than generated by studies of low-dose vaginal products, and major menopause societies have stated that the warning is not supported by the evidence for these preparations. It is widely regarded as first-line treatment. Whether it is appropriate for you, particularly with a history of hormone-sensitive cancer, is a conversation for your physician.
Do laser or energy-based vaginal treatments work?
The honest answer is that the evidence is limited and contested. In 2018 the FDA issued a safety communication warning that energy-based devices were being marketed for vaginal rejuvenation and related indications without having been cleared for them, and noting reports of adverse events including burns and persistent pain. Some subsequent sham-controlled trials have not shown benefit over placebo. There may be a role for selected patients, but these treatments should not be presented as established, and they should not displace a trial of treatment that has stronger support.
Reviewed by Daniel Moghadam, M.D., founder and medical director of Modern Aesthetica. Last reviewed October 2026. These symptoms have several possible causes and some require examination and diagnosis. Bleeding after menopause always needs prompt medical assessment. Nothing here is a substitute for a consultation.
Modern Aesthetica
8907 Wilshire Blvd, Suite 270, Beverly Hills, CA 90211
Phone: (213) 895-4730
Hours: Mon–Thu 10:00am–5:00pm · Fri 9:00am–5:00pm · Sat & Sun closed
Serving Beverly Hills, West Hollywood, Santa Monica, Brentwood, Hollywood and greater Los Angeles.
